Wednesday, May 27th, 2015
The controversial smoking cessation drug Champix has been linked to suicidal side-effects but, according to a leading Adelaide respiratory researcher, Champix is safe and can improve someone’s chances of kicking the habit.

Speaking in the lead up to World No Tobacco Day (Sunday 31 May), Kristin Carson encourages the use of Champix (or Varenicline Tartrate) for smokers admitted into hospital with a smoking-related illness.

“Smoking accounts for 15% of all deaths, 80% of all lung cancers and is responsible for the greatest disease burden in Australia,†says Ms Carson, from The Queen Elizabeth Hospital (Basil Hetzel Institute for Translational Health Research), who has recently completed PhD research into quitting smoking at the University of Adelaide.

“Champix was made available to Australian smokers in 2008 and has a dual effect – it eases cravings and reduces the ‘pleasure’ of smoking. However, American studies in 2007 linked Champix to nasty side effects like thoughts of suicide, suicidal behaviour, erratic behaviour and drowsiness.

“In our Adelaide-based study, we found that people who took Champix in conjunction with attending counselling had better control over their cravings and had lower levels of anxiety while quitting, compared to patients who only attended counselling. And, after the 12-week program, 31% of the patients on Champix had quit smoking compared to 21% of the patients who attended counselling only,†she says.

Ms Carson says in the study she led, no one experienced suicidal thoughts but there were some side-effects.

“The patients on Champix experienced higher levels of nausea, abnormal dreams, headaches and insomnia than those who didn’t take the drug. However, most of these side effects were only experienced by a small number of patients and no one reported having suicidal thoughts,†says Ms Carson.

“It’s important that those who are quitting smoking, particularly when they are using medication like Champix, also use counselling. A counsellor, such as those available via Quit SA on the phone, can monitor the patient’s symptoms and any side effects, and consulting with a counsellor improves the chances of successfully quitting,†she says.

Ms Carson says smokers looking to quit should weigh up their options and choose a method that’s best for them.

“There are lots of options for people who want to quit smoking and the best place to start is However, for those who are finding it particularly hard to quit, Champix should be considered,†says Ms Carson.

This research was published in the journals Nicotine and Tobacco Research and Thorax, and was funded by the Department of Respiratory Medicine at The Queen Elizabeth Hospital.

Media Contact:

Kristin Carson
Senior Medical Research Scientist
The Queen Elizabeth Hospital
(Basil Hetzel Institute for Translational Health Research)
PhD student
The University of Adelaide
Mobile: +61 (0)402 396 707
[email protected]

Kate Bourne
Media and Communications Officer
The University of Adelaide
Phone: +61 8 8313 3173
Mobile: +61 (0)457 537 677
[email protected]

Contact Profile


NewsMaker is an Australian Press Release Distribution and Social Media Marketing service founded in 2004. The company today represents over 22,000 brands who seek to share their content with journalists, bloggers and the community.

Newsmaker Editors
P: +61 414 69 70 71


controversial stop-smoking drug Champix safe



More Formats

View QR Code